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1. Introduction 
One of the effective approaches to develop new anticancer drugs is to prepare polymer-
anticancer drug conjugates. The polymer-anticancer drug conjugates include polymer-
protein conjugates, polymer-drug conjugates and supramolecular drug-delivery systems. In 
1975, the concept of a polymer-drug conjugate was first proposed by Ringsdorf (Ringsdorf, 
1975). In his model, a bioactive anticancer agent was attached to a suitable polymeric carrier, 
directly or through a biodegradable linker. Currently developed delivery systems for 
anticancer agents encompass colloidal systems (liposomes, emulsions, nanoparticles and 
micelles), polymer implants and polymer conjugates. These delivery systems are able to 
provide enhanced therapeutic efficacy and reduce toxicity of anticancer agents mainly by 
altering the pharmacokinetics and biodistribution of the drugs (Kim & Lim, 2002). The idea 
is attractive and could form the basis of a new generation of anticancer agents (Sugahara et 
al., 2007).  
Many polymers have been investigated as carriers for conjugates,  including poly(glutamic 
acid), poly(L-lysine), poly(malic acid), poly(aspartamides), poly((N-hydroxyethyl)-L 
glutamine), poly(ethylene glycol), poly(styrene-co-maleic acid/anhydride), poly(N-(2-
hydroxypropyl) methacrylamide) copolymer, poly(ethyleneimine), 
poly(acroloylmorpholine), poly(vinylpyrrolidone), poly(vinylalcohol), poly(amidoamines), 
divinylethermaleic anhydride/acid copolymer, dextran, pullulan, mannan, dextrin, 
chitosan, hyaluronic acid and proteins etc.. Coupling low molecular weight anticancer drugs 
to high or low molecular weight polymers is an effective method for improving the 
therapeutic index of clinically used agents.  
Several candidates have been evaluated in clinical trials, such as N-(2-hydroxypropyl) 
methacrylamide conjugates of doxorubicin, camptothecin, paclitaxel, and platinum (II) 
complexes (Haag & Kratz, 2006). The conjugation of cytotoxic agents to a hydrophilic 
polymer may convey several advantages, (1) increased water solubility; (2) protection from 
hydrolysis and proteolysis; (3) prolonged half-life and enhanced bioavailability of drug; (4) 
reduction of toxicity, immunogenicity and antigenicity; (5) controlled release or specific 
targeting through an enhanced permeability and retention (EPR) effect. In the chapter, we 
will focus on poly (L-glutamic acid)-paclitaxel (PG-PTX), which can improve the therapeutic 
index, pharmacokinetic properties, safety and efficacy of paclitaxel (PTX). 
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2. The anticancer agent PTX 
PTX, an anticancer agent isolated from the trunk bark of the Pacific Yew tree, Taxus brevifolia, 
shows a wide spectrum of anticancer activity for a variety of human cancers, including breast, 
ovarian, non-small-cell lung, prostate, head and neck, colon cancers and so on (Rowinsky, 
1997). PTX can induce mitotic arrest and apoptosis in proliferating cells by targeting tubulin, 
which is a component of the mitotic spindle. PTX binds to the N-terminal 31 amino acids of the 
ǃ-tubulin subunit and prevents depolymerization. As a result, the mitotic spindle is disabled, 
cell division can not be completed, and the cell replication in the late G2 or M phase of the cell 
cycle is inhibited. The cancer cells are killed by disrupting the dynamics necessary for cell 
division (Bhalla, 2003). The anticancer mechanism of PTX is shown in Fig. 1. 
The clinical use of PTX is limited by its high hydrophobicity, low solubility, high systemic 
exposure, poor pharmacokinetic characteristics, and the lack of selective tumor uptake 
(Parveen & Sahoo, 2008; ten Tije et al., 2003). The clinical use of PTX also leads to many side 
effects. Side effects of PTX include nausea, vomiting, diarrhea, mucositis, myelosuppression, 
cardiotoxicity, neurotoxicity and hypersensitivity reactions, and the latter two are mainly 
owing to polyoxyethylated castor oil (Cremophor® EL) and ethanol used for solubilizing 
PTX (Rogers, 1993; Sugahara et al., 2007). PTX for injection is supplied in 50% Cremophor® 
EL and 50% dehydrated ethanol.  
Despite premedication with corticosteroids and antihistamines, PTX still induces minor 
reactions (e.g., flushing and rash) in approximately 40% of patients and major potentially 
life-threatening reactions in 1.5%−3% of patients (Lemieux et al., 2008; Price & Castells, 
2002). Hydrophobicity of PTX is also associated with unfavorable kinetics, high levels of 
protein binding, and high volumes of distribution often greatly exceeding total body water. 
Together, all these factors have a negative impact on the therapeutic index because only a 
small proportion of the drug administered actually reaches the tumor site (Singer, 2005). As 
mentioned above, the efficacy and tolerability of PTX are limited by its low solubility, high 
systemic exposure, and the lack of selective tumor uptake.  
 
 
Fig. 1. Schematic illustration of PTX anticancer mode: heterdimers of ǂ- and ǃ-tubulin 
assemble to form a highly dynamic microtubule which plays an extremely important role in 
the process of mitosis (A); microtubule-targeted paclitaxel binds along the interior surface of 
the microtubule, suppressing its dynamics mitosis (B). 
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3. The EPR effect and endocytosis of polymer-drug conjugates 
Anticancer polymer-drug conjugates can be divided into two targeting modalities: passive 
and active. While clinical anticancer activity has been achieved by passive macromolecular 
drug delivery systems, further selectivity is possible by active targeting (Luo & Prestwich, 
2002). Polymer-drug conjugates can promote passive tumor targeting by EPR effect and 
allow for lysosomotropic drug delivery following endocytic capture of the drugs (Greco & 
Vicent, 2008).  
The view that the polymer-drug conjugates passively accumulate in tumor tissues because 
EPR effect is clearly supported by the electron microscopic observation that the peripheral 
tumor vascular endothelium has quantitatively more fenestrations and open junctions 
than normal vessels (Li, 2002; Roberts & Palade, 1997). Tumor vasculature is more 
permeable to macromolecules than normal vasculature because the structures between the 
neovasculature in tumors and the mature vasculature in normal organs are different 
(Roberts & Palade, 1997; Singer, 2005). The paucity of lymphatic vessels in tumor tissues 
allows the retention of these macromolecules in the interstitial space, which leads to 10 to 
100-fold increase in intratumoral drug concentrations for a prolonged time when 
compared with an equivalent dose of the anticancer drug given according to the 
conventional methods.  
The phenomenon of EPR effect is applicable for almost all rapidly growing solid tumors and 
it has been widely used in cancer-targeting drug design (Iyer et al., 2007; Maeda et al., 2000; 
Reddy, 2005). The EPR effect is molecular weight (MW) - and size-dependent and is most 
effective with agents whose MWs are 50 000 or greater, which is above the threshold for 
renal excretion. Due to the different pathways to enter the cells between the small molecule 
drugs and the macromolecule drugs, multi-drug resistance (MDR) can be minimized at the 
same time (Boddy et al., 2005; Greish et al., 2003; Shaffer et al., 2007). Because of the stronger 
metabolic activity of the cancer cells, in addition to the EPR effect, cancer cells show a higher 
degree of uptake of macromolecules by endocytosis than normal cells (Li, 2002). The process 
of EPR and endocytosis is illustrated in Fig. 2. 
4. PG-PTX conjugate 
4.1 Modified formulations of PTX 
Because of the unfavorable properties of PTX, it is urgent to develop a more effective 
strategy to improve its water solubility and selectivity towards tumor tissues (Maeda et al., 
2009). Several approaches have been utilized to increase the therapeutic index of PTX. More 
water-soluble formulations of PTX have been investigated, including a nanoparticulate 
formulation (ABI-007), a polymeric micellar formulation (Genexol-PM), and a liposomal 
formulation and covalent linkage to macromolecule polymers that alter the 
pharmacokinetics of the parent drug (Ibrahim et al., 2002; Kim et al., 2004; Soepenberg et al., 
2004).  
4.2 The formation and the anticancer mechanism of PG-PTX 
PG-PTX (paclitaxel poliglumex, CT-2103, Xyotax®, Opaxio®) is a water-soluble 
macromolecular conjugate that links PTX with PG (Li et al., 1996). PTX is conjugated by 
ester linkage to the Ǆ-carboxylic acid side chains, leading to a relatively stable conjugate (Li 
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et al., 1998a). Because the conjugation site is the 2 hydroxyl group of PTX, which is a crucial 
site for tubulin binding, the conjugate does not interact with ǃ-tubulin and is inactive (Li, 
2002; Rogers, 1993). The median MW of PG-PTX is 38.5 kDa, with a PTX content of 
approximately 36% on a w/w basis, equivalent to about one PTX ester linkage per 11 PG 
units of the polymer (Fig. 3) (Bonomi, 2007; Rogers, 1993).  
Morphological analysis and biochemical characterizations demonstrate that both PTX and 
PG-PTX are able to induce apoptosis in cells expressing wild-type p53 or mutant p53, to 
arrest cells in the G2/M phase of the cell cycle, and to down-regulate HER-2/neu 
expression. Furthermore, when PG-PTX is compared with other water-soluble derivatives of 
PTX, including small-molecular-weight sodium pentetic acid-PTX and polyethylene glycol-
PTX conjugate (MW 5 kDa), they all show the same effects on telomeric association, mitotic 
index chromatin condensation, and formation of apoptotic bodies (Multani et al., 1999). 
These results indicate that PG-PTX has the same mechanisms of action as PTX. 
 
 
Fig. 2. Illustration of EPR effect and endocytosis. Different from blood vessels in normal 
tissue (A), those in tumor tissue (B) have porous openings, through which large-size 
conjugate leaks and is preferentially trapped and distributed to the tumor tissue. Once in the 
tumor tissue, the conjugate is taken up by the tumor cells through a cellular process called 
endocytosis (C). The conjugate releases active agent (D) via metabolism by lysosomal 
enzymes inside the lysosome of the tumor cell. 
4.3 PG as the carrier of PG-PTX 
Compared with other synthetic polymers that have been tested in clinical studies, PG is 
unique because it is composed of natural L-glutamic acid linked together through amide 
bonds rather than the nondegradable C-C backbone. The free Ǆ-carboxyl group in each 
repeating unit of L-glutamic acid is negatively charged under a neutral pH condition, which 
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makes the polymer water-soluble. The carboxyl groups can also provide functionality for 
drug attachment. PG is not only water-soluble and biodegradable, it is also nontoxic. All 
these characteristics make PG a unique candidate as the carrier of polymer-drug conjugates 
for selective delivery of chemotherapeutic agents, especially for PTX (Parveen & Sahoo, 
2008).  
 
O
O
NHBz O
O
N
H
H
N
H
N
O
O
O
HO HOO O
a b
y
AcO
OH
O
HO
O
AcO
H
OBz
a and b can = 0a + b averages 10  
Fig. 3. Schematic representation of PG-PTX structure. The structure shown is illustration of a 
fragment of the molecule. On average there are approximately 10 non-conjugated monomer 
glutamic acid units (a + b) for every molecule conjugated to a PTX molecule (y).  
4.4 The metabolism of PG-PTX 
PG-PTX conjugate is stable in the systemic circulation but can be broken down by 
intracellular lysosomal enzymes to release the drug after entering cells by endocytosis. The 
proposed mechanism by which PG-PTX is metabolized includes endocytosis of the polymer-
drug conjugate followed by intracellular release of active PTX by proteolytic activity of the 
lysosomal enzyme cathepsin B, an exocarboxydipeptidase, and diffusion of PTX into the 
nucleus (Turk et al., 2001). The process is presented in Fig. 4. This finding may have 
biological relevance as expression of cathepsin B is upregulated in malignant cells, 
particularly during tumor progression period (Podgorski & Sloane, 2003). These data 
support a model in which PG-PTX accumulates in tumor tissues through the EPR effect, 
followed by the cathepsin B-mediated release of PTX. The kinetics of intracellular formation 
of several PG-PTX metabolites have been quantified in vitro and have been found to be 
largely dependent on cathepsin B. Metabolites that have been detected in vivo include 
diglutamyl-PTX and monoglutamyl-PTX. Monoglutamyl-PTX is an unstable compound that 
can be nonenzymatically degraded to release free PTX. Specific enzyme inhibitors such as 
CA-074 methyl ester, a cell-permeable irreversible inhibitor of cathepsin B, and EST, a cell-
permeable irreversible inhibitor of cysteine proteases, dramatically decrease the formation 
of monoglutamate PTX and unconjugated PTX in tumor cells that have been incubated with 
PG-PTX (Rogers, 1993).  
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Fig. 4. Metabolism of PG-PTX by endocytosis and enzymatic degradation. 
4.5 The advantages of PG-PTX 
4.5.1 PG-PTX reduces the side effects of PTX in clinical application 
Compared with PTX, the solubility, uptake, tumor retention, and anticancer efficacy of 
PG-PTX are increased. Many clinical studies so far have confirmed several advantages of 
PG-PTX in the treatment of cancer patients. This macromolecular conjugate PG-PTX 
eliminates the need for Cremophor® EL and, therefore, decreases infusion time and the 
risk of hypersensitivity. Compared to standard taxanes, PG-PTX in phase I and phase II 
studies shows encouraging outcomes with reduced neutropenia and alopecia, and allows 
a more convenient administration schedule without the need for routine premedications 
(Rogers, 1993). PG-PTX induces hypersensitivity reactions in less than 1% of patients, 
without premedication, and only rare severe reactions have been reported. Furthermore, 
patients undergoing PG-PTX therapy have a better quality of life, because there is no 
significant hair loss, nerve damage, or neutropenia at the current dose. PG-PTX is water-
soluble and can be administrated rapidly as a 10 -20 min infusion rather than hours when 
administrating PTX. The recommended phase II dose of PG-PTX is 235 mg/m2 every 3-
week administered over a 10 min infusion without premedication (Sabbatini et al., 2004). 
Twenty-six patients were treated with PG-PTX in the Phase I study of PG-PTX 
administered weekly for patients with advanced solid malignancies. The recommended 
dose of PG-PTX for subsequent disease-directed studies is 70 mg/m2 weekly. Most 
patients experienced at least one drug-related adverse event during the study (Table 1) 
(Mita et al., 2009). Ninety-nine patients were treated with PG-PTX in a multi-center phase 
II study of PG-PTX as an intravenous (i.v.) infusion (approximately 10 min) at a dose of 
175 mg/m2 on day 1 of each 3-week cycle. And the treatment-related adverse events 
including non-laboratory-based and laboratory-based maximum CTC toxicities in all 
cycles are listed in Table 2. 
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Grade 1 Grade 2 Grade 3 Total 
Adverse event -70 mg/m2  
Neutropenia 1(13%) 1(13%) 2(25%) 
Anemia 1(13%) 1(13%) 2(25%) 
Peripheral neuropathy 2(25%) 2(25%) 2(50%) 
Anorexia 1(13%) 1(13%) 
Diarrhea 1(13%) 1(13%) 
Nausea 1(13%) 1(13%) 
Pain in limb 1(13%) 1(13%) 
Fatigue 1(13%) 1(13%) 
Adverse event-all cohorts  
Neutropenia 2(8%) 3(12%) 5(19%) 
Anemia 1(4%) 1(4%) 2(8%) 4(15%) 
Peripheral neuropathy 5(16%) 4(8%) 1(4%) 10(38%) 
Anorexia 1(4%) 1(4%) 2(8%) 
Diarrhea 3(12%) 1(4%) 1(4%) 5(19%) 
Nausea 3(12%) 1(4%) 4(15%) 
Rash 1(4%) 2(8%) 3(12%) 
Myalgia 3(12%) 2(8%) 5(19%) 
Pain in limb 1(4%) 1(4%) 2(8%) 
Fatigue 4(15%) 3(12%) 7(27%) 
Hypersensitivity 1(4%) 1(4%) 2(8%) 
Table 1. Adverse events related to PG-PTX administration (n = 26). 
 
Grade 1 Grade 2 Grade 3 Grade 4 
Non-laboratory-based maximum CTC 
toxicity, all cycles
    
Neuropathy 20 15 15 0 
Fatigue 10 19 5 0 
Musculoskeletal 11 10 1 0 
Myalgia/arthralgia 7 5 1 0 
Nausea 21 4 1 0 
Stomatitis/mucositis 7 1 1 0 
Hoarseness 0 0 1 0 
Drug hypersensitivity 5 8 1 0 
Laboratory-based maximum CTC toxicity, all 
cycles 
    
Neutropenia 20 14 15 9 
Leukopenia 13 18 18 0 
Anemia 46 18 6 0 
Abbreviation: CTC, National Cancer Institute Common Toxicity Criteria. 
Table 2. Treatment-related adverse events (n = 99). 
4.5.2 PG-PTX promotes anticancer efficacy and reduces toxicity by prolonging tumor 
exposure and minimizing systemic exposure to active drug 
A single i.v. injection of PG-PTX at its maximum tolerated dose (MTD) equivalent to 60 mg of 
PTX/kg and at a lower dose equivalent to 40 mg of PTX/kg results in the disappearance of an 
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established implanted 13762F mammary adenocarcinoma (mean size, 2000 mm3) in rats. 
Similarly, mice bearing syngeneic OCa-1 ovarian carcinoma (mean size, 500 mm3) are tumor-
free within 2 weeks after a single i.v. injection of PG-PTX at a dose equivalent to 160 mg of 
PTX/kg (Li et al., 1998b). MTD of PTX in rats and mice are 20 mg/kg and 60 mg/kg, 
respectively. In contrast, MTD of a single i.v. injection of PG-PTX in rats and mice are 60 
mg/kg and 160 mg/kg, respectively. MTD of PG-PTX was approximately 160 mg/kg to 200 
mg/kg in immunocompetent mice and 120 mg/kg to 150 mg/kg in immunodeficient animals. 
At their respective MTDs, single-dose PG-PTX is more efficacious than PTX in Cremophor® 
EL/ethanol (Li et al., 1999). PG-PTX has shown anticancer activity in preclinical studies with 
human tumor xenografts and in early phase I trials. MTD of PG-PTX as a single agent, based 
on the first cycle toxicity of patients, is 235 mg/m2 (Verschraegen et al., 2009). Biodistribution 
in mice bearing OCa-1 tumor treated with i.v. injections of tritium-labeled PG-[3H] PTX shows 
a five times greater distribution of PTX to tumor tissues than those treated with PTX (Li et al., 
2000c), which was demonstrated by whole-body autoradiograph (Fig. 5). 
 
 
Fig. 5. Whole-body autoradiographs of mice killed 1 day (A) and 6 days (B) after tail vein 
injection of PG-[3H]PTX. Most radioactivity was localized to tumor periphery at 1 day after 
injection, but by day 6, radioactivity had diffused into the center of the tumor. L: liver; M: 
muscle; Arrow head: tumor. 
Preclinical studies in animal tumor models demonstrate that PG-PTX is more effective than 
PTX and it is associated with prolonged tumor exposure but minimized systemic exposure to 
the active drug. The slow release of the active drug from a well-designed polymer carrier 
results in sustained high intratumoral drug levels and lower plasma concentrations of the 
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active drug. To accomplish this, the polymer conjugate should release the active drug in tumor 
tissues rather than in the plasma during circulation. As a result, exposure of normal tissues 
will be limited, which is potentially associated with a more favorable toxicity profile (Li et al., 
2000c). Thus, enhanced tumor uptake and sustained release of PTX from PG-PTX in tumor 
tissues are major factors contributing to its markedly improved in vivo anticancer activities.  
4.5.3 The favorable pharmacokinetic properties of PG-PTX 
The superior anticancer activity of PG-PTX in preclinical studies suggests that PG-PTX 
might have favorable pharmacokinetic properties. Many studies suggest that PG-PTX exerts 
the anticancer activity by the continuous release of free PTX, and that the favorable 
pharmacokinetics of PG-PTX conjugate in vivo is likely the main cause contributing to its 
advanced anticancer activity (Oldham et al., 2000). Female mice with subcutaneous B16 
murine melanomas are given PG-[3H] PTX at the equivalent dose 40 mg/kg of [3H] PTX i.v. 
infusion. Tumor samples are collected at regular intervals up to 144 h after infusion, and the 
concentrations of PG-PTX and PTX are determined by LC/MS analysis. Tumor exposure to 
total taxanes is increased by a factor of 3 (Cmax) or a factor of 12 (AUC) in mice treated with 
PG-[3H] PTX compared with the mice treated with [3H] PTX (Table 3) (Chipman et al., 2006). 
PG-[3H] PTX has a much longer half-life in plasma than [3H] PTX (Fig. 6).  
Whereas PTX has an extremely short half-life in the plasma of mice (t1/2 = 29 min), the 
apparent half-life of PG-PTX is prolonged (t1/2 = 317 min) (Li et al., 1998b). In clinical trials, 
PG-PTX is given as a 30-min infusion every 3 weeks. Patients were treated at dose levels 
ranging from 30 mg/m2 to 720 mg/m2. PG-PTX is detectable in plasma of all patients and 
has a long plasma half-life of up to 185 h, and the results are consistent with preclinical 
findings. Furthermore, concentrations of free PTX released from PG-[3H] PTX remain 
relatively constant up to 6 d after infusing. Moreover, peak plasma concentrations of free 
PTX are less than 0.1 μM 24 h after PG-PTX administration at doses up to 480 mg/m2 (176 
mg/m2 PTX equivalents) (Boddy et al., 2001).  
 
 
Fig. 6. Tumor concentration of [3H]paclitaxel after treatment with PG-[3H] PTX and [3H] 
paclitaxel in female mice with s.c. B16 melanomas at a dose of 40 mg paclitaxel. 
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In another phase I study, PG-PTX is administrated at 70 mg/m2. The mean maximal 
concentration (Cmax) is 41.2 ± 8.60 μg/mL and the Cmax is reached right after the end of the 
infusion. The plasma concentration declines with a mean terminal half-life of 15.7 ± 3.17 h. 
The mean AUC at the MTD is 455 ± 112 μg/h/mL and the mean average systemic plasma 
clearance is 0.16 ± 0.04 L/h/m2 (Sabbatini et al., 2004). At the MTD, the mean volume of 
distribution at steady state and during the terminal phase are 1.41 ± 0.28 L/m2 and 3.62 ± 
1.13 L/m2, the mean Cmax of unconjugated PTX is 0.21 ± 0.07 μg/mL, the mean Tmax is 0.56 ± 
0.18 h, the mean terminal half life is 16.6 ± 7.85 h, and the mean AUC is 3.15 ± 1.16 
μg/h/mL. The ratio of the free PTX AUC to the conjugated PTX AUC is 0.7%. The plasma 
concentration of PTX released from PG-PTX increases largely in proportion to the dose and 
remains similar after repeated administration (Sabbatini et al., 2004). 
 
 Cmax (μg/g) Tmax (h) AUC (μg/h/g) MRT (h) 
PG-[3H] PTX     
Total taxanes 72.0 4 4547 51 
PTX 4.0 72 345 66 
[3H] PTX     
Total taxanes 26.7 1.5 384 23 
PTX 22.4 1.5 261 17 
Table 3. Preclinical tumor pharmacokinetics. 
4.5.4 PG-PTX facilitates the radiotherapy and chemotherapy 
Preclinical studies in animal tumor models demonstrate the enhanced safety and efficacy 
of PG-PTX relative to PTX when administered as a single agent or in conjunction with 
radiation. Studies show that PG-PTX given 24 h before or after radiotherapy enhances 
tumor growth delay significantly more than PTX. PG-PTX dramatically potentiates tumor 
radiocurability after single-dose or fractionated irradiation without affecting acute normal 
tissue injury. PG-PTX increases the therapeutic ratio of radiotherapy more than that 
previously reported for other taxanes (Milas et al., 2003). PG-PTX not only can produce a 
much stronger radiopotentiating effect than PTX, the kinetics of its radiopotentiating 
effect is also different from that of PTX. Delays in the growth of syngeneic murine ovarian 
OCa-1 tumors grown intramuscularly in C3Hf/Kam mice are used as the treatment end 
point.  
PG-PTX given 24 h before tumor irradiation increases the efficacy of tumor radiation by a 
factor of more than 4 (Li et al., 2000a). Furthermore, the combination of radiation and PG-
PTX can produce a significantly greater tumor growth delay than treatment with radiation 
and PTX when both drugs are given at the same equivalent PTX dose of 60 mg/kg 24 h after 
tumor irradiation (enhancement factors, 4.44 versus 1.50) (Li et al., 2000b). When the 
treatment end point is tumor cure, the enhancement factors are 8.4 and 7.2 of fractionated 
and single dose radiation, respectively. These values are greater than those produced by 
other taxanes or by any other chemotherapeutic drugs or radiosensitizer tested so far. PG-
PTX may exert its radiopotentiation activity through increased tumor uptake of PG-PTX and 
sustained release of PTX in the tumor (Li et al., 2000a). To determine whether prior 
irradiation affects tumor uptake of PG-PTX, PG-[3H] PTX is injected into mice with OCa-1 
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tumors 24 h after 15 Gy local irradiation (Li et al., 2000b). The uptake of PG-[3H] PTX in 
irradiated tumors is 28%−38% higher than that in nonirradiated tumors at different times 
after PG-[3H] PTX injection, indicating that tumor irradiation can increase the accumulation 
of PG-PTX in the tumors (Fig. 7).  
Anticancer activity in patients who have failed previous chemotherapy, including PTX 
treatment, is observed with PG-PTX (Sabbatini et al., 2004). Ninety-nine patients in a multi-
center phase II study treated with PG-PTX as an i.v. infusion approximately 10 min at a dose 
of 175 mg/m2 on day 1 of each 3-week cycle have received at least one cycle of treatment. 
Response rates categorized by platinum sensitivity are shown in Table 4. 
 
 
Fig. 7. Effects of combined radiation and PG-PTX and radiation and PTX on the growth of 
OCa-1 tumors in mice. 
  
No. of Regimens 
Response 
PR SD PD 
No. of 
Patients
(%)
No. of 
Patients
(%)
No. of 
Patients 
(%) 
Platinum-sensitive, n = 42       
1 or 2 prior regimens 5/18 28 6/18 33 7/18 39 
≥3 prior regimens 1/24 4 11/24 46 12/24 50 
Total 6/42 14 17/42 40 19/42 45 
Platinum-resistant/refractory, n = 57       
1 or 2 prior regimens 2/21 10 4/21 19 15/21 71 
≥3 prior regimens 2/36 6 11/36 31 23/36 64 
Total 4/57 7 15/57 26 38/57 67 
Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease. 
Table 4. Response by Platinum Sensitivity. 
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5. Summary 
Clinical proof of concept for polymer conjugates has already been achieved over the last 
three decades, with a family of polymer-protein conjugates reaching the market and a 
growing list of polymer-drug conjugates currently in clinical studies. The application of 
polymer-anticancer drug conjugates in anticancer treatment is a promising field with 
growing opportunities to achieve medical treatments with highly improved therapeutic 
value (Vicent et al., 2008). PG-PTX conjugate can improve the anticancer activity, enhance 
the safety and efficacy, ameliorate the pharmacokinetic properties and so on. Therefore, the 
application of PG-PTX facilitates the clinical therapy of a variety of human cancers.  
However, many challenges still exist, providing opportunities to improve this platform 
technology further. The clinical development of anticancer agents utilizing various delivery 
systems is actively undergoing. New technologies and multidisciplinary approaches to 
develop advanced drug delivery systems, applicable to a wide range of anticancer agents, 
may eventually lead to an effective cancer therapy in the future. 
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